Health Care • Biotechnology: Pharmaceutical Preparations
$5.45 ▼ -0.31
(-5.38%)
MKT CAP: $38.9M • VOL: 204.1K
52W L $2 52W H $7
ROARABLE / RQD
E • 26/100
PIOTROSKI
2 / 9
GRDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $36.3K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$657.4K | — | — |
| Gross Margin % | -50.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.1M | -$15.6M | -$15.8M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$6.4M | -$18.1M | -$15.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.7M | -$9.2M | -$12.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.7M | -$9.2M | -$12.4M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -20.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $899.8K | $163.5K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $28.8M | -$3.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GRDX.